Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05352763 · ClinicalTrials.gov registry record · Phase 2
Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease
A Phase 2 study, sponsored by Cassava Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT05352763 is a Phase 2 study that was terminated before completion, run by Cassava Sciences. The registered enrollment target is 90 participants.
The verdict
NCT05352763, a Phase 2 study, was terminated before completion, sponsored by Cassava Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
This is a 96-week extension study of open-label simufilam 100 mg b.i.d. for mild-to-moderate Alzheimer's disease subjects who completed the Phase 2 study, PTI-125-04. The study will evaluate safety and long-term treatment. Safety will be assessed by AE monitoring, clinical labs, urinalysis, vital signs, ECGs, and C-SSRS.
Interventions
- DRUG simufilam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2022-05-12 |
| Est. Completion | 2024-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05352763
The ClinicalTrials.gov registry entry for NCT05352763 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cassava Sciences, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which simufilam is the first listed.
NCT05352763 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05352763 about?
NCT05352763 is a clinical study titled "Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease". This is a 96-week extension study of open-label simufilam 100 mg b.i.d. for mild-to-moderate Alzheimer's disease subjects who completed the Phase 2 study, PTI-125-04. The study will evaluate safety and long-term treatment. Safety will be assessed by AE monitoring, clinical labs, urinalysis, vital si...
What is the current status of trial NCT05352763?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2022-05-12. Estimated completion is 2024-12-31.
What interventions are being tested in trial NCT05352763?
The interventions under investigation include: simufilam (DRUG).
Who is sponsoring clinical trial NCT05352763?
This trial is sponsored by Cassava Sciences, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.